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Abstract
Objective: To assess the feasibility and effectiveness of
transjugular intrahepatic route aspiration thrombectomy
and catheter-directed thrombolytic therapy in patients
with acute superior mesenteric venous thrombosis.
Materials and methods: During a period of 8 years, 12
patients with acute thrombosis of the superior mesenteric
vein (SMV) were treated by transjugular intrahepatic
approach. The mean age was 41.2 years. After access to
the portal system via the transjugular approach, the
pigtail catheter fragmentation of the thrombus, local
urokinase injection, and manual aspiration thrombec-
tomy were used for treatment of the SMV thrombosis
initially, followed by continuous thrombolytic therapy
via an indwelling infusion catheter in the SMV, which
was performed for 2 to 6 days (4.2 ± 1.8 days). The
adequacy of anticoagulation was performed during
treatment, throughout hospitalization, and after dis-
charge. Results: Technical success was achieved in all 12
patients. Substantial clinical improvement was seen in
these patients after the procedure. Minor complications
at the jugular puncture site were observed in 4 patients,
but the thrombolytic therapy was not interrupted. Con-
trast-enhanced computed tomography (CT) scan before
discharge demonstrated nearly complete disappearance
of SMV thrombosis in all patients. The 12 patients were
discharged 5–10 days (7.6 ± 2.0) after admission. Mean
duration of follow-up after hospital discharge was
37.7 months, and no recurrent episodes of SMV throm-
bosis developed during that time period. Conclusion:
Catheter-directed thrombus aspiration, mechanical
fragmentation, and local thrombolytic infusion via the
transjugular intrahepatic route is a safe and effective
therapy for the management of patients with acute
symptomatic SMV thrombosis.
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Acute superior mesenteric vein (SMV) thrombosis is an
uncommon and insidious disease that is potentially lethal
because its presenting symptoms overlap with those of
many other diseases, leading to signiﬁcant delays in
diagnosis and therapy. Among all mesenteric ischemic
events, mesenteric venous thrombosis accounts for 5%–
15% [1, 2]. There are no uniform protocols for the
effective treatment of SMV thrombosis.
Generally, if the patient is suspected to have bowel
infarction, an immediate exploratory laparotomy is
needed. In patients without evidences of bowel infarction
or perforation, systemic anticoagulation with heparin
and supportive care are initial treatments [3–6]. How-
ever, systemic anticoagulation is of limited value in pa-
tients with acute extensive thrombosis of the SMV. Acute
SMV thrombosis is still associated with 25% of extra-
hepatic portal vein hypertension and 18% transmural
bowel infarction despite systemic anticoagulation [2].
Recently, endovascular selective catheterization
thrombolytic therapy has been performed with increas-
ing success. Endovascular thrombolytic therapy can be
administered directly via percutaneous transhepatic [7–9]
or transjugular intrahepatic routes [10–13] or indirectly
via superior mesenteric artery (SMA) infusion of
thrombolytic agents [14–16]. The objective of the present Correspondence to: Mao Qiang Wang; email: wangmq@vip.sina.com
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DOI: 10.1007/s00261-010-9637-1study is to report the clinical outcome of 12 patients with
acute symptomatic SMV thrombosis who were treated
by catheter-directed thrombolysis with tranjugular
intrahepatic route at our hospital.
Materials and methods
The study was approved by the Institutional Review
Board at our hospital. The potential risks and beneﬁts of
the procedure were explained, and informed consent was
obtained from each patient.
Patients
Between October 2000 and November 2008, using the
transjugular intrahepatic route, we treated 12 patients (4
women, 8 men) with a mean age of 41.2 years (range
18–75 years) who had symptomatic SMV thrombosis.
All 12 patients had experienced acute symptoms of less
than 3 weeks (range, 2–16 days; average, 8.0 days).
The following information was collected for each
patient: demographic data, presenting symptoms, date of
symptom onset, hospitalization and diagnosis, potential
causative factors for the thrombosis, therapy and
response to therapy, duration of hospitalization, and
results at last follow-up.
The presenting symptoms are listed in Table 1. The
most common symptom was abdominal pain, which was
present inall12patients.Sevenofthese patientspresented
with severe abdominal pain; 5 of these patients presented
with vague (n = 1) or moderate (n = 4) abdominal pain
that progressively worsened. Other presenting symptoms
includedabdominaldistension(n = 6),anorexia(n = 9),
nausea (n = 8), vomiting (n = 4), melena (n = 3), diar-
rhea (n = 1), and low-grade fever (n = 2). All patients
were hemodynamically stable, and no clinical signs of
peritonitis were noted at abdominal examination.
Anidentiﬁableetiologicfactorwasfoundin10ofthese
patients (Table 1). Four patients underwent splenectomy
because of liver cirrhosis with portal hypertension and
gastroesophageal variceal bleeding. The interval between
the onset of symptoms of the SMV thrombosis and sple-
nectomy was 22, 30, 32, and 40 days, respectively. The
other potential causative factors included serum protein S
deficiency (n = 2), protein C deficiency (n = 1), anti-
phospholipid antibody syndrome (n = 1), hyperhemo-
globinemia(n = 1),anddeepvenousthrombosis(n = 1).
Diagnostic evaluation
Increased white cell counts (12.5 ± 2.5 9 10
3/mm
3;
range, 12.5–17.5 9 10
3/mm
3) was found in 4 patients at
Table 1. Summary of clinical data
Pt.
No.
Age/
sex
(years)
Symptoms Etiologies Indication for intervention Days from
symptoms
to admission
Days from
symptoms to
intervention
1 18/M Severe midabdominal pain,
distension, nausea, anorexia
Serum protein S deficiency Persistent pain despite
anticoagulation
68
2 44/M Severe abdominal pain,
anorexia, distension, nausea
Post-splenectomy day 22,
PLT420 9 10
3/mm
3
Continued pain, despite
anticoagulation
71 0
3 52/F Moderate abdominal pain,
nausea, vomiting, anorexia,
progressively worsened
Post-splenectomy day 30,
PLT540 9 10
3/mm
3
Progressive pain, despite
anticoagulation
11 14
4 62/M Severity of midabdominal pain,
distension, nausea, anorexia
Serum protein S deficiency Severity of symptoms despite
anticoagulation
57
5 75/M Vague midabdominal pain,
distension, anorexia
progressively worsened
Unknown Continued pain, despite
anticoagulation
12 14
6 36/F Moderate abdominal pain,
nausea, anorexia,
progressively worsened
Post-splenectomy day 32,
PLT380 9 10
3/mm
3
Continued pain, despite
anticoagulation
16 19
7 32/M Severe colicky abdominal pain,
nausea, vomiting, anorexia
Post-splenectomy day 40,
PLT300 9 10
3/mm
3
Worsening pain, despite
anticoagulation
68
8 24/F Moderate abdominal pain,
vomiting, diarrhea
progressively worsened
Serum protein C deficiency Severity of symptoms despite
anticoagulation
46
9 28/M Moderate midabdominal pain,
progressively worsened,
anorexia, melena
Antiphospholipid syndrome Worsening pain, despite
anticoagulation
10 13
10 49/F Severe abdominal pain, disten-
sion, nausea, low-grade fever
A history of DVT,
4 months previously
Persistent pain, distension,
despite anticoagulation
91 2
11 43/M Severe midabdominal pain,
nausea, melena, low-grade
fever
Hyperhemoglobinemia,
hemoglobin 21.5 g/dL
Continued pain, despite
anticoagulation
46
12 31/M Severe midabdominal, pain,
vomiting, distension, anorexia
Unknown Continued acuity of symptoms,
despite anticoagulation
68
DVT deep venous thrombosis, PLT platelet
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agglutination assay in all 12 patients on admission, and
the D-dimer levels were >500 lg/L (range, 80–480 lg/L;
cut-off value, ‡500 lg/L) in 5 patients, with range of
550–1420 lg/L. Normal values were detected for
thrombin time, C-reactive protein, serum D-lactate, and
amylase.
Ultrasonography (US) and computed tomography
(CT) were performed in all 12 patients. All patients had
SMV thrombosis, which was conﬁrmed by the imaging
study. Mild ascites was identiﬁed in 3 patients. Esopha-
gogastro-duodenoscopy was normal in 10 patients, mild
varices in 2 patients.
Initial management
All patients were treated initially with bowel rest and
nasogastric suction, intravenous ﬂuid administration,
broad-spectrum prophylactic antibiotics (including ampi-
cillin, gentamycin, and metronidazole), and intravenous
heparin adjusted to maintain the activated partial throm-
boplastin time between 2.0 and 2.5 times control.
Systemic anticoagulation after the diagnosis of SMV
thrombosis was assessed for 2 days in 7 patients, and for
3 days in 5 patients; however, the symptoms continued
(n = 7) or worsened (n = 5). After discussion with the
surgery and medicine departments, and given the lack of
clinical and radiographic suspicion for bowel infarction,
plus systemic anticoagulation was ineffective, these pa-
tients were referred to the interventional radiology
department for catheter-directed thrombolysis to achieve
rapid restoration of the SMV flow. Mean duration from
onset of symptoms to catheter-directed thrombolytic
therapy was 10.4 days (Table 1).
Indications and contraindications to
interventional procedure
In our hospital, the catheter-directed thrombolysis was
employed in patients with acute SMV thrombosis, which
involved the main trunk of the SMV, with severe
symptoms, and/or persistent symptoms or worsening the
abdominal pain despite anticoagulation.
The exclusion criteria of the tranjugular intrahepatic
route included patients with evidences of bowel infarction
or perforation, unfavorable anatomy (such as complete
thrombosed portal vein, or portal venous cavernous
transformation, and marked atrophy of the liver), and
patient with high risk for bleeding.
Endovascular techniques. Before the transjugular
approach was attempted, the portal system was studied
with indirect portography obtained during the venous
phase following iodinated contrast medium injections in
the SMA and the splenic artery.
The transjugular approach was carried out according
to the technique previously described [10, 11] by using
US and fluoroscopic guidance of the portal vein punc-
ture. Following infiltration of local anesthesia, a Rosch-
Uchida set (Cook, Bloomington, IN, USA) was used to
gain access to the portal vein branch. Once the catheter
was placed inside a portal branch, the thrombus of the
SMV could be traversed with the aid of a 4-Fr Cobra
catheter (Cordis, the Netherlands) and a 0.035-inch
hydrophilic guidewire (Terumo, Japan). After reaching
distal branches of the SMV, the Cobra catheter was ex-
changed for an 8 mm diameter angioplasty balloon
catheter (Boston Scientific, MA, USA), to open up a
channel, and then a 10-Fr Rosch-Uchida sheath (Cook)
was put into the portal trunk. A bolus of 3000 IU of
heparin was injected via a peripheral venous catheter.
Through the 10-Fr sheath, an angled 8-Fr guiding
catheter (Cordis) was used to aspirate as much of the
thrombus as possible from the SMV with a Luer-Lok 60-
mL syringe. The aspiration procedure was performed
from distal to proximal clots in 8–12 cycles (10 ± 2).
Simultaneously, a 5-Fr pigtail catheter (Cordis) was used
to fragment the thrombus with ‘‘spinning technique’’ [17]
and an injection of urokinase (Tianjin Biochemical
Pharmaceutical Co., Ltd, China) 200,000-300,000 IU
using a hand-pulse spray technique.
Following the mechanical aspiration procedure, a
4-Fr multiple side-hole catheter (Angiodynamics,
Queensbury, NY, USA) was placed with the tip in the
SMV, and then continuous thrombolytic therapy was
started with urokinase 50,000 IU/h. Heparin infusion
was given simultaneously via a peripheral venous cath-
eter, at a dose of 1000 IU/h. The adequacy of antico-
agulation was adjusted to maintain the activated partial
thromboplastin time between 2.0 and 2.5 times the
control, during treatment and throughout hospitaliza-
tion. During the prolonged infusion of thrombolytics,
patients had the SMV venographic follow-up via the
infusion catheter every 24 h. Color Doppler ultrasound
scan (CDUS) assessment of PV and SMV patency was
performed at 24, 48, and 72 h, 1 week following the
procedure, and at discharge. Follow-up contrast-
enhanced CT was carried out in each patient before the
infusion catheter removal.
Termination of the infusion of thrombolytics was
based on clinical improvement and radiographic ﬁnd-
ings. The catheter infusion of thrombolytics was dis-
continued after the patients’ symptoms (i.e., abdominal
pain, anorexia, distension, and nausea) had improved
sufﬁciently that they were able to begin oral intake, and
the repeated venography demonstrated restoration of
blood ﬂow in the SMV, and CT follow-up conﬁrmed
complete or nearly complete lysis of the SMV throm-
bosis. The patients were then placed on chronic antico-
agulation with warfarin adjusted to maintain an
International Normalized Ratio of 2–3 after discharge.
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2–3 months in the ﬁrst year, and every 4–6 months in the
second year. Follow-up contrast-enhanced CT was car-
ried out at discharge, at every 3 months for 1 year, and
at 6–12 months thereafter.
Technical success was deﬁned as successful catheter-
ization of the SMV, removal of the majority of clots, and
restoration of ﬂow in the SMV. Clinical success was
deﬁned as relief of symptoms and bowel resection was
not required after the procedure.
Results
Technical success
Technical success was achieved in all 12 patients (Fig. 1).
Mean procedural time was 75 ± 15 min (range 50–95).
Using pigtail catheter fragmentation, local urokinase
injection, and manual aspiration thrombectomy of the
SMV thrombosis resulted in restoration of blood flow in
the main SMV, which was documented on immediate
follow-up direct SMV venography.
After the mechanical thrombolysis, continuous
thrombolytic therapy via the indwelling catheter in the
SMV was performed for 2–6 days (4.2 ± 1.8 days).
Mean total dose of urokinase infusion was 5.0 million IU
(range 2.6–7.2). Duration of the SMV urokinase infusion
is listed in Table 2.
On completion of the SMV urokinase infusion, sig-
niﬁcantly improved ﬁlling of the SMV was seen in all 12
patients (Figs. 2, 3), which was confirmed by repeated
venography via the infusion catheter. Contrast-enhanced
CT images obtained before discharge demonstrated
nearly complete lysis of SMV thrombosis in all patients.
In addition, CT images showed improvement in edema
of the intestine and mesentery in all patients (Fig. 4).
Mild ascites, detected in 3 patients before the throm-
bolysis procedure, disappeared at discharge.
Complications
During urokinase infusion via the indwelling catheter in
the SMV, minor complications at the internal jugular
vein puncture site were observed in four patients: a small
hematoma was observed in three patients, and a small
amount of oozing of bloody ﬂuid was observed in one
patient. We simply applied light compression with sterile
gauzes on the puncture site without interruption of the
Fig. 1. A 24-year-old woman with moderate peri-umbilical
abdominal pain, vomiting, and diarrhea for 4 days. A Selected
axial image from admission contrast-enhanced CT shows
massive thrombus within the SMV (straight arrows). B Pre-
treatment digital subtraction SMA angiogram with delayed
(venous) phase shows no visualization of the trunk of the
SMV (straight arrows), and remarkable pooling of contrast
medium in the branches of the SMV (curved arrows). C Pre-
treatment direct venography via transjugular approach access
to portal vein shows massive thrombosis of the proximal SMV
(straight arrows) and dilated jejunal veins (curved arrows).
D Follow-up direct SMV venography via the infusion catheter,
obtained 2 days after the SMV urokinase infusion, shows the
widely patent SMV (straight arrows). E. CT image at the same
level as in A, obtained 2 days after the SMV infusion of
thrombolytics, shows the patent SMV with only minimal
residual wall thrombus (curved arrow). Note the infusion
catheter within the SMV (straight arrow).
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bleeding or arterial puncture site bleeding.
Clinical improvement
Sufﬁcient clinical improvement, characterized by pro-
gressive decrease in abdominal pain, nausea, and
distension, was seen in all 12 patients after 12–24 h of the
mechanical thrombolysis procedure. Clinical improve-
ment continued during the thrombolytic therapy via the
indwelling infusion catheter in the SMV. No patient
required bowel resection after the procedure. The 12
patients were discharged 5–10 days (7.6 ± 2.0) after
admission.
Follow-up
Mean duration of follow-up after hospital discharge was
37.7 months (range 12–72 months). All 12 patients are
alive at writing, and no recurrent episodes of the SMV
thrombosis developed during the follow-up period.
Chronic anticoagulation with oral warfarin was initiated
in all patients at least 6 months (range 6–12 months)
after hospital discharge. During the 12–72 months of
follow-up, CDUS and contrast-enhanced CT conﬁrmed
the patency of the SMV.
Long-term oral aspirin was given at a dose of 100 mg/day
to 4 patients who had splenectomy. Lifelong oral war-
farin was suggested to the patients with deﬁciencies of
serum protein S and protein C, and antiphospholipid
antibody syndrome.
Discussion
The exact mechanism and natural history of SMV
thrombosis remain unclear. An identiﬁable etiology may
be found in approximately 75% of patients, with as many
as 56% of patients having identiﬁable coagulopathy [1,
2]. Most commonly, thrombosis of the SMV is a mani-
festation of a hypercoagulable state resulting from or
exacerbated by an event such as pancreatitis or abdom-
inal surgery. Thrombophilic conditions associated with
the SMV thrombosis include deficiencies of antithrombin
III, protein C, and protein S; factor V Leiden and pro-
thrombin gene mutation; and the antiphospholipid
antibody syndrome [3–5]. In our series, 10 (83.3%)o f1 2
patients had potential causative factors, including sple-
nectomy in 4, deficiency of serum protein S in 2, and
other causes in 4 patients.
In symptomatic SMV thrombosis patients, treatment
depends on the presence or absence of clinical and
imaging peritoneal signs [5, 6, 18]. An emergency lapa-
rotomy with resection of necrotic bowel is necessary in
the former condition and anticoagulant and/or throm-
bolytic therapy in the latter condition. In patients with-
out evidence of bowel infarction or perforation, systemic
anticoagulation with heparin and supportive care com-
prises the initial treatment [1, 2]. In our 12 patients, the
diagnosis was made relatively early on presentation, yet
the initial clinical and radiologic findings were impressive
and suggestive of advanced disease. We chose the inter-
ventional procedure to treat these patients because sys-
temic anticoagulation was ineffective.
Endovascular catheter-directed thrombolytic therapy
has been proposed as a minimally invasive treatment
option for patients with acute symptomatic SMV
thrombosis [7–13]. With this approach, the SMV
thrombosis can be managed by pharmacologic throm-
bolysis and/or mechanical thrombectomy. For pharma-
cologic thrombolysis, possible routes of treatment
include indirect intra-arterial infusion of thrombolytic
Table 2. Patient with SMV infusion of urokinase and clinical outcome
Pt.
No.
Total
UK
dose
a
Duration
of UK
infusion (days)
Complication Outcome of
CT follow-up
Length of
hospital stay
(days)
Length of
follow-up
(months)
Follow-up results
1 3.6 3 None Complete 7 28 No recurrence
2 4.8 4 None Complete 8 12 No recurrence
3 6.0 5 None Complete nearly 9 66 No recurrence
4 4.8 4 None Complete 7 26 No recurrence
5 6.0 5 A small hematoma at
the IJV puncture site
Complete 9 38 No recurrence
6 7.2 6 A little oozing of bloody
fluid at the IJV puncture site
Complete nearly 10 62 No recurrence
7 4.8 4 None Complete nearly 7 46 No recurrence
8 2.6 2 None Complete 5 72 No recurrence
9 6.0 5 A small hematoma at the
IJV puncture site
Complete nearly 9 18 No recurrence
10 4.8 4 None Complete nearly 8 34 No recurrence
11 6.0 5 A small hematoma at the
puncture site
Complete 7 20 No recurrence
12 3.8 3 None Complete 5 30 No recurrence
UK urokinase, IJV internal jugular vein
a Million IU
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portal vein, by the transjugular [10–13] or transhepatic
routes [7–9].
Indirect thrombolytic therapy via the SMA is less
technically demanding and has been described for its
potential beneﬁts in infusing thrombolytic agents into
small mesenteric venous branches [15, 16]. However, this
approach does not allow direct infusion into the
thrombus, may result in lytic agents diverting through
patent branches and collaterals, and possible prolonga-
tion of the total infusion time via the SMA [8–10], which
may result in an increased risk of bleeding. In addition,
the potential risk of thrombosis or embolization in the
SMA and SMA branches is increased during prolonged
catheterization.
Direct access to the portal vein by a transjugular or
transhepatic route directly targets the SMV thrombosis,
leading to fast removal of the thrombus and ﬂow
improvement, and an improvement of symptoms [14, 15,
19]. Compared to indirect method, lysis by direct access
to the SMV has advantages: it is more efficient, is less
time-consuming, and decreases the dose of the throm-
bolytic agent, lowering the risk of related complications
[8, 12, 16, 17]. Catheter-directed thrombolysis in addition
to anticoagulation should offer the advantage of im-
proved lysis [5, 6, 20]. Equally important, re-establish-
ment of antegrade flow, even incomplete, likely reduced
the patients’ risk of developing bowel infarction and al-
lowed the additional time needed for infusion of
thrombolytics and anticoagulation therapy.
Percutaneous transhepatic access is technically rela-
tively easy and allows the maneuver of mechanical de-
vices compared with transjugular intrahepatic access.
Usually, this approach is suitable for the removal of
larger thrombus within the trunk of the SMV. The
drawbacks of the percutaneous transhepatic route in-
Fig. 2. A 44-year-old man with severe abdominal pain, dis-
tension, anorexia, and nausea for 7 days. He had undergone
splenectomy 22 days previously. A Selected axial image from
admission contrast-enhanced CT shows massive thrombus
within the SMV (straight arrow). Note the edema of the small
bowel (curved arrow). B Pre-treatment direct venography via
transjugular approach access to portal vein shows massive
thrombosis of the proximal SMV (straight arrows) extending
into the main PV (arrows). Note the stump of the splenic vein
(curved arrow). C Immediate follow-up direct portal venogra-
phy via a pigtail catheter, after the catheter fragmentation,
local urokinase injection, and aspiration of the SMV throm-
bosis, shows good flow from the SMV (straight arrows) into
the portal vein. Note the minimal residual wall thrombus in the
main PV (curved arrow). D CT image at the same level as in
A, obtained 4 days after the SMV urokinase infusion, shows
widely patent SMV (curved arrow). Note the infusion catheter
within the SMV (straight arrow).
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hepatic hemorrhage [15, 17, 19, 21]. This is likely to occur
given that the transhepatic route requires traversing the
hepatic capsule and is followed by thrombolysis and
possibly systemic anticoagulation. In spite of portal vein
access via a small peripheral branch and embolization of
the tract during access removal, a subcapsular hemor-
rhage could not be avoided with this approach [15, 21,
22]. In this situation, anticoagulation therapy had to be
interrupted.
Our 12 patients treated with the transjugular intra-
hepatic route demonstrated the feasibility of this route to
the management of this challenging illness. The transju-
gular approach access to the portal vein is generally
performed with the creation of a transjugular intrahe-
patic portosystemic shunt; this approach is usually
indicated for patients with cirrhosis with portal hyper-
tension caused by portal vein thrombosis [11, 12].
Compared to the percutaneous transhepatic approach,
the transjugular intrahepatic approach does not require
traversing the hepatic capsule, and thus would eliminate
the risk of subcapsular hemorrhage. Furthermore, the
transjugular intrahepatic approach is safer in patients
with ascites and anticoagulation. Our 12 patients were
placed on adequate anticoagulation, which rendered
them unsuitable for the percutaneous transhepatic ap-
proach. Although we did not observe significant bleeding
complications in our patients with the transjugular
intrahepatic approach, significant intra-abdominal
bleeding is a potential serious complication [23, 24].
In patients with acute extensive SMV thrombosis,
mechanical thrombectomy could initially be used to de-
bulk the thrombus, and pharmacologic thrombolysis
would probably still be necessary in most cases to treat
residual thrombosis and to treat thrombus in the small
and peripheral veins [17, 20]. The combination of aspi-
ration thrombus and local pharmacological thrombolysis
via a direct access to the SMV is more effective in pa-
tients with extensive SMV thrombosis compared to di-
rect mechanical thrombectomy alone [8, 10, 20]. In our
12 patients, aspiration the thrombus associated with an
indwelling catheter infusion of thrombolytics into the
SMV was effective, resulted in a rapid improvement in
symptoms, recanalization of the SMV, and resolution of
symptoms.
Combining thrombolytic infusion with anticoagula-
tion would appear to increase the risk of bleeding and
hemorrhage [22, 25, 26]. A study by Ouriel et al. [25]
described the complication rates for patients with lower-
extremity arterial or venous occlusions treated with local
urokinase or rt-PA. Overall, 15% required transfusion
and 1.2% developed intracranial hemorrhage, which was
fatal in 8 of 9 cases. In our series, no significant bleeding
complications occurred. This may have resulted from the
relatively low dose infusion of urokinase via the catheter
in the SMV, no simultaneous peripheral venous infusion
Fig. 3. A 43-year-old man with
severe midabdominal pain,
nausea, and fever for 4 days.
A Selected axial image from
admission contrast-enhanced CT
shows thrombus (straight arrows)
within the SMV. Note the dilated
and thickened small bowel loop
(curved arrow). B Pre-treatment
direct venography via
transjugular approach access to
portal vein shows extensive
thrombosis of the proximal SMV
(straight arrows). C Follow-up
direct portal venography via the
infusion catheter, obtained
5 days after the SMV urokinase
infusion, shows good flow from
the SMV into the portal vein. Note
the minimal residual wall
thrombus in the main SMV
(straight arrows). D CT image at
the same level as in A, obtained
5 days after the SMV urokinase
infusion, shows patent SMV
(straight arrows) with only
minimal residual wall thrombus.
396 M. Q. Wang et al.: Acute symptomatic mesenteric venous thrombosisof urokinase, and careful monitoring of the coagulation
status during treatment.
Endovascular catheter-directed thrombolytic therapy
can offer a non-surgical alternative for the treatment of
acute symptomatic SMV thrombosis. However, this can
only be performed in a selected group of patients who do
not present with transmural bowel infarction and perito-
nitis, or who are not at risk for bleeding, and who have
persistent symptoms or worsening of symptoms despite
anticoagulation [1, 2]. Minimally symptomatic or asymp-
tomatic patients with the SMV thrombosis may best be
treated with systemic anticoagulation only. Prompt sur-
gical intervention should be undertaken if the patient’s
condition deteriorates or clinical signs of peritonitis
develop during the interventional treatment [2, 6]. The
patients in our series had severe disease evidenced by
radiographicfindingsandseveresymptoms. Otherfactors
included worsening symptoms despite anticoagulation.
Theresultsobtainedinourpatientseriescanbeconsidered
satisfactory. All 12 patients showed a patent SMV,
without recurrent episodes, during a mean follow-up of
37.7 months.
The limitations of this study include the lack of a
control group, randomization, and uniformity of evalu-
ation and treatment. Because of the small sample size, no
statistically signiﬁcant conclusions could be drawn
regarding treatment with respect to dosages of throm-
bolytic agent or heparin, techniques, or underlying risk
factors.
In summary, the combination of catheter fragmen-
tation of thrombus, aspiration thrombectomy, and
indwelling catheter infusion of thrombolytics via trans-
jugular intrahepatic access to the portal system, is a safe
and effective therapy for the management of patients
with acute symptomatic SMV thrombosis. All 12 pa-
tients had subjective improvement in symptoms, had
objective radiographic evidence of thrombolysis, and
avoided bowel resection. Because of the small size of the
study, the ability to generalize the results is limited.
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